PrEP

HIV prevention drug should be targeted toward women at risk, too

Antiretroviral drug Truvada would benefit at-risk women, too, says CDC. (Justin Sullivan/Getty Images)

Nearly 500,000 women could benefit from the drug Truvada, the name for the HIV prevention drug known generically as PrEP, or pre-exposure prophylaxis, the CDC said recently. Since the drug was released in 2012, it has been widely publicized among gay men as a pill they could take once a day to prevent HIV infection. But hundreds of thousands of other potential candidates for the drug, including intravenous drug users and women, have not been as quick to begin taking the drug. Trans women, in particular, could benefit from the drug, according to the Daily Beast, which cited statistics noting that one in three trans women have been diagnosed with HIV and their infection risk is 50 times higher than other adults.

The drug has been controversial since it was released in 2012, with some high-profile AIDS activists including Larry Kramer dismissing it before finally signing a statement this year that he supported it. The drug’s $13,000-a-year sticker price (if not covered by insurance) has also made its creator, Gilead Pharmaceuticals, the target of heavy criticism and petitions to lower the price and make the life-saving drug available to more vulnerable populations.

Read the full story at The Daily Beast.

Related:
Weighing the Sheen effect: How worried are women about H.I.V. these days?
Elizabeth Taylor ran a “secret underground” HIV medication network
How H.I.V. affects women in the United States

Leave a Reply

Your email address will not be published. Required fields are marked *